Literature DB >> 11865536

[Central serous chorioretinopathy: a new extragastric manifestation of Helicobacter pylori?: Analysis of a clinical case].

C Giusti1.   

Abstract

Central serous chorioretinopathy is classically characterized by a shallow, round, serous detachment of the macular retina. It preferentially affects men between 20 and 45 years of age and recurrences have been documented in most cases. Although the aetiopathogenesis of the disease is still unknown, it has been thought to be due to a focal leakage from one or more defects in the retinal pigment epithelium, which allow serous fluid from the choriocapillaris to diffuse into the subretinal space. Moreover, it is theorized that damage of the active fluid transport mechanisms through the retinal pigment epithelium may also play a contributing role. Finally, the reported correlation with psychophysical stress provides support for the concept of the disease being "adrenergically conditioned". Recently, an interesting association has been observed between this chorioretinal pathology and the Helicobacter pylori infection and, consequently, a new etiological hypothesis has been proposed. Here we report a retrospective analysis of a clinical case of central serous chorioretinopathy with Helicobacter pylori positivity.

Entities:  

Mesh:

Year:  2001        PMID: 11865536

Source DB:  PubMed          Journal:  Clin Ter        ISSN: 0009-9074


  10 in total

Review 1.  Central serous chorioretinopathy: update on pathophysiology and treatment.

Authors:  Benjamin Nicholson; Jason Noble; Farzin Forooghian; Catherine Meyerle
Journal:  Surv Ophthalmol       Date:  2013 Mar-Apr       Impact factor: 6.048

Review 2.  Helicobacter pylori as a risk factor for central serous chorioretinopathy: Literature review.

Authors:  Aránzazu Mateo-Montoya; Martine Mauget-Faÿse
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

3.  Clinical efficiency of Helicobacter pylori eradication in the treatment of patients with acute central serous chorioretinopathy.

Authors:  Olesya Zavoloka; Pavlo Bezditko; Irina Lahorzhevska; Darya Zubkova; Yevgeniya Ilyina
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-03-16       Impact factor: 3.117

Review 4.  Oral medications for central serous chorioretinopathy: a literature review.

Authors:  William Fusi-Rubiano; Habiba Saedon; Vijay Patel; Yit C Yang
Journal:  Eye (Lond)       Date:  2019-09-16       Impact factor: 3.775

5.  Helicobacter pylori as a potential target for the treatment of central serous chorioretinopathy.

Authors:  Antonio Marcelo Barbante Casella; Rodrigo Fabri Berbel; Gláucio Luciano Bressanim; Marcus Rudolph Malaguido; José Augusto Cardillo
Journal:  Clinics (Sao Paulo)       Date:  2012-09       Impact factor: 2.365

6.  The effect of Helicobacter pylori treatment on remission of idiopathic central serous chorioretinopathy.

Authors:  Mohammad Bagher Rahbani-Nobar; Alireza Javadzadeh; Leila Ghojazadeh; Mandana Rafeey; Amir Ghorbanihaghjo
Journal:  Mol Vis       Date:  2011-01-11       Impact factor: 2.367

Review 7.  Helicobacter pylori infection and eye diseases: a systematic review.

Authors:  Sergio Claudio Saccà; Aldo Vagge; Alessandra Pulliero; Alberto Izzotti
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

8.  Association of Helicobacter pylori with central serous chorioretinopathy in Iranian patients.

Authors:  Mohammad Roshani; Nasrin Ahangar Davoodi; Mohammad Reza Seyyedmajidi; Homayoun Zojaji; Somayeh Jahani Sherafat; Massih Hashemi; Mohammad Reza Zali
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2014

9.  The relation between Helicobactor pylori gastrointestinal tract infection and central serous chorioretinopathy among patients in Al-Diwaniya province.

Authors:  Haider A Layikh; Saif A Saeed; Hasanen H Attar
Journal:  Saudi J Ophthalmol       Date:  2022-02-18

10.  The effect of eradicating Helicobacter pylori on idiopathic central serous chorioretinopathy patients.

Authors:  Yalong Dang; Yalin Mu; Manli Zhao; Lin Li; Yaning Guo; Yu Zhu
Journal:  Ther Clin Risk Manag       Date:  2013-09-02       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.